Investigational muvalaplin (Eli Lilly), the first oral therapy being developed to lower lipoprotein (a) levels, was shown to reduce levels in a phase 1 trial, with no safety concerns, researchers ...

Muvalaplin, an oral drug, significantly reduces Lp(a) levels by disrupting apo(a) and apoB bonding, achieving up to 85.5% reduction in a phase 2 study. Lp(a) is a genetically driven cardiovascular ...

Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of ...

Eli Lilly (LLY) and Company announced “positive” Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a), or Lp(a), a genetically ...

About The Study: Muvalaplin was not associated with tolerability concerns and lowered lipoprotein(a) (Lp[a]) levels up to 65% following daily administration for 14 days in this first-in-human phase 1 ...

Muvalaplin, a novel oral medication, safely and effectively lowers high levels of lipoprotein(a), or Lp(a), results from the phase 2 KRAKEN trial show. Concentrations of Lp(a) cholesterol are ...

Late-phase trials of targeted therapies for elevated lipoprotein(a) are nearing completion, with the first readouts expected ...

"While muvalaplin appears to be an effective approach to lowering Lp (a) levels, we still need to study whether Lp (a) lowering will result in fewer heart attacks and strokes." The study had ...

Reduction in levels seen using an intact lipoprotein(a) assay and apolipoprotein(a)-based assay. (HealthDay News) — Muvalaplin reduces lipoprotein(a) levels, according to a study published online in ...

Lipoprotein(a) has been linked to aortic stenosis and atherosclerosis. Lipoprotein(a) is formed by the interaction of apolipoprotein(a) with apolipoprotein B100. Muvalaplin, a small molecule drug, ...

On 18 November 2024, at the American Heart Association's (AHA) 2024 conference in Chicago, Illinois, US, during a late-breaking session on the topic of New Targets and New Treatments: Advances in ...

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...